Context: Clinical use of single serum gonadotropin measurements in children is limited by the pulsatile secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). However, first morning voided (FMV) urine may integrate the fluctuating gonadotropin serum levels.
levels increase through the pubertal transition, which in turn stimulates gonadal maturation and subsequent production of sex steroids (3, 4) .
The measurement of basal or GnRH-stimulated levels of serum gonadotropins is used in the diagnostic workup of children and adolescents with pubertal disorders to evaluate the activity of the HPG axis (3, 5) . However, basal as well as GnRH-stimulated FSH and LH levels have some drawbacks: Although a single random serum sample is simple, its interpretation is challenged by fluctuating basal gonadotropins levels, and lower values are inconclusive (6) . The GnRH stimulation test, considered the gold standard for diagnosing pubertal disorders, is a procedure that requires hospitalization, and only few normative data for GnRH-stimulated values exist (7) . Moreover, GnRH agonist (GnRHa) is not readily available worldwide (5) .
As an alternative, noninvasive method for evaluating the function of the HPG axis, measurement of the gonadotropin concentrations in first morning voided (FMV) urine has been proposed (8, 9) . It has been shown that gonadotropin concentrations in serum increase overnight in a pulsatile fashion just before and throughout puberty (10, 11) , and FMV urine is expected to reflect this elevated nocturnal secretion (9, 12) .
The aim of this study was to describe and evaluate urinary gonadotropin levels according to age, sex, and pubertal stage in healthy children and adolescents. Furthermore, we sought to evaluate whether analysis of gonadotropins in FMV urine could serve as a noninvasive substitute for the invasive GnRH stimulation test in diagnostic workup and therapeutic management in girls with central precocious puberty (CPP).
Subjects and Methods

Healthy boys and girls
Healthy children from the COPENHAGEN Puberty Study (ClinicalTrials.gov ID NCT01411527) (13, 14) were included in this study. The children and young adolescents underwent a thorough clinical examination, including evaluation of Tanner stages (15, 16) , and a detailed medical history, including use of oral contraceptives (in girls), was recorded as previously described in detail (13, 14) . In boys, the testicular volumes were evaluated by palpation using a Prader orchidometer (16) . In girls, breast stages (B1 to B5) were estimated by palpation. A testicular volume of $4 mL in boys and a breast stage of $B2 in girls defined pubertal onset. Nine hundred twenty-four healthy white children (516 girls and 408 boys) collected FMV urine of .30 mL and had a paired serum sample taken on the same day. A total of 81 were excluded from the dataset because the urine sampling time did not represent an overnight collection period (a valid overnight collection period corresponded to last voiding previous to the FMV occurring between 3 PM and 12 PM and the FMV occurring between 5 AM and 11 AM the following day) (n = 78), there was a lack of Tanner staging (n = 2), and one postmenarcheal girl was considered to have an extreme urinary LH outlier value (urinary LH of 142 IU/L) corresponding to a midluteal LH peak and was therefore excluded. Blood and urinary sampling was randomly collected during menstrual cycle in postmenarcheal girls. The remaining 479 girls (age 5.8 to 19.1 years, mean 10.6 years) and 364 boys (age 6.1 to 19.4 years, mean 10.9 years) were included in the study. Seven girls were on oral contraceptives and were excluded in the statistical analyses when calculating reference ranges.
Girls with precocious puberty
Thirty-five girls referred with clinical signs of puberty ,8 years were included in this study. All 
Blood analyses
Serum samples were drawn from an antecubital vein and clotted and centrifuged immediately after. The serum samples were stored at 220°C until final analyses. Basal and peak serum FSH and LH were measured by the same time-resolved immunofluorometric assays (Delfia; PerkinElmer, Boston, MA) with detection limits of 0.06 IU/L for FSH and 0.05 IU/L for LH. Intra-assay and interassay coefficients of variations were ,5% in both gonadotropin assays.
Urine analyses
The time of last void before the FMV and of the FMV were recorded by the participants. The total volumes of the FMVs were recorded when the samples were received in the laboratory. Then 80 mL of bovine serum albumin and 150 mL of glycerol were added to a 2-mL sample from each individual urine collection. The urine was then stored at 220°C until final analysis. Urinary FSH and LH concentrations were measured in all FMV urine samples using the same immunofluorometric assays as used for serum samples. The lower limit of detection of urinary FSH was 0.06 IU/L and urinary LH was 0.05 IU/L. To adjust for the variation in hours between previous void and the FMV, urinary FSH and LH levels expressed as amount excreted in 8 hours (IU/8 h) were calculated by using the formula:
Both unadjusted concentrations and the calculated amounts excreted per 8 hours were evaluated and presented.
Osmolality was measured in 108 FMV urine samples to adjust for urinary dilution and to study the impact of osmolality on results. The advantage of this method is that osmolality directly relates to the number of particles in the urine, and in contrast to creatinine excretion, osmolality is not affected by variation between sex, body mass index, and age. Osmolality is therefore generally a good marker of renal function and reflects the hydration status of an individual with a normal renal function (18) . Urinary osmolality was measured by the freezing point depression method using an automatic cryoscopic osmometer (Osmomat 030 from Gonotec, Berlin, Germany). Mean urinary osmolality for the 108 urine samples was 0.788 Osm/kg with a standard deviation (SD) of 0.230. The median (range) osmolality of all urine samples included in this study was 0.804 (0.287 to 1.214) Osm/kg. Osmolality corrected urinary FSH and LH correlated strongly with uncorrected concentrations (r = 0.964 and r = 0.93, respectively, both P , 0.001), with no impact of level (for details see correlation and Bland-Altman plot, Supplemental Fig. 1 ). Therefore, data are presented as uncorrected urinary FSH and LH concentrations, respectively.
Statistical analyses
Concentrations below the detection limits were for statistical purpose set to detection limit divided by 2, corresponding to 0.03 for serum and urinary FSH, and 0.025 for serum and urinary LH.
To define reference ranges for the healthy children's urinary and serum concentrations of FSH and LH according to age, sex, and pubertal stage, percentile curves were estimated using the General Additive Model for Location Scale and Shape (19) . To account for measurements below the detection limit, these measurements were treated as left-censored.
The Bland-Altman plot was used to assess the importance of the osmolality correcting the urine sample concentrations. To assess whether there were correlations between the basal and GnRH-stimulated gonadotropin levels in serum and FMV urine, Spearman correlations were used.
The diagnostic validity of the urine analysis was evaluated by receiver operating curve (ROC) analyses, which also allowed estimation of the optimal cut-off point for sensitivity and specificity in the diagnosis of CPP. The nonparametric Mann-Whitney U test was performed to assess the differences in the distributions of the FSH and LH concentrations in urine and serum between the pubertal stages among the healthy children and between the diagnoses (CPP and PT) among the patients.
Statistical analyses were performed using SPSS software (IBM, version 22) and R (R Core Team, R Foundation for Statistical Computing, Vienna, Austria, version 3.3.2) as previously described (20) .
Ethical considerations
The study was approved by the Regional Ethical Committees (KF 01 282214 and KF 11 2006 KF 11 -2033 . All children and parents have given their informed written consent.
Results
Urinary gonadotropins according to age, sex, and pubertal status Individual serum and urinary FSH and LH concentrations in healthy girls and boys are shown according to age, sex, pubertal status, and use of oral contraceptives (girls) in Fig. 1 and 2 , respectively. FSH was detectable in 208 out of 208 urine samples from prepubertal girls (100%) and in 236 out of 237 urine samples from prepubertal boys (99.6%). LH was detectable in 187 out of 208 urine samples from prepubertal girls (89.9%) and 212 out of 237 urine samples from prepubertal boys (89.5%). Significant increases were observed with advancing age and pubertal maturation in both sexes for urinary FSH and LH levels expressed as concentration (IU/L) as well as amount excreted per 8 hours (IU/8 h). Specific age-and sex-related means and reference ranges are presented in Supplemental Tables 1 and 2 . Larger interindividual variations in urinary FSH and LH excretion were observed among pubertal girls compared with pubertal boys (Figs. 1  and 2 ). Use of oral contraceptives resulted in low or lownormal serum and urinary FSH and LH levels, although mostly within normal ranges (Figs. 1 and 2) . Urinary FSH and LH (IU/L) correlated with serum FSH and LH concentrations (IU/L) in girls (r = 0.692, P , 0.001 and r = 0.880, P , 0.001) and boys (r = 0.822, P , 0.001 and r = 0.885, P , 0.001), respectively.
Children with puberty disorders
Serum and urinary concentrations of FSH and LH in girls with PT and CPP are shown according to age and agerelated reference ranges (Fig. 3) . Urinary excretion of LH was significantly elevated in 9 out of 12 children with CPP compared with the prepubertal reference range, whereas urinary LH was within reference ranges in 12 out of 13 of girls with PT (Fig. 3) . Urinary FSH excretion was not elevated in girls with CPP and PT. The urinary concentration of LH of the patients correlated strongly to their basal (r = 0.871, P , 0.001) and GnRH-stimulated peak serum LH levels (r = 0.820, P , 0.001) (Supplemental Fig. 2 ). Agerelated urinary LH SD scores were significantly higher in girls with CPP compared with girls with PT [P = 0.002, Fig. 4(b) ]. An ROC illustrates the diagnostic properties of basal serum LH and urinary LH for separating girls with CPP (peak LH . 5 IU/L) vs PT (peak LH , 5 IU/L) [ Fig. 4(a) ].
Basal and GnRH-stimulated peak serum LH and urinary LH levels were increased at baseline and declined significantly following 12 weeks of GnRHa treatment (Fig. 5) . Urinary LH concentrations were suppressed to values within the age-matched reference range in all girls treated with GnRHa.
Discussion
Based on our large population-based study of 843 healthy children and adolescents, we present extensive age-, sex-, and puberty-related reference ranges for urinary concentrations of FSH and LH. Additionally, we found elevated urinary LH excretion in girls with precocious puberty, which suppressed to levels within reference ranges in all girls after treatment with GnRHa. In agreement with previous studies, we suggest measurement of urinary excretion of gonadotropins as a noninvasive alternative to the GnRH stimulation test in the diagnosis and monitoring of treatment in girls with precocious puberty.
Measurement of urinary gonadotropins in puberty has previously been studied as a potential alternative to invasive serum measurement (21, 22) ; however, to our knowledge, no studies have presented comprehensive data on reference ranges for paired urine and serum samples from .800 healthy children and adolescents. Previous smaller population-based studies have demonstrated that urinary gonadotropins can reflect the activity of the HPG axis and thereby distinguish prepubertal children from pubertal adolescents (22, 23) .
We found an increase in both urine and serum gonadotropin levels with advancing age as seen in other studies (9, 22, (24) (25) (26) . Importantly, we found that the gonadotropin increase in morning urine was detectable before the clinical manifestation of puberty, and before a corresponding increase in serum gonadotropin levels in accordance with the findings of Demir et al. (9) .
The larger interindividual variation in urinary FSH and LH excretion we observed among pubertal girls most likely reflects that our urine collections were not timed according to the menstrual cycle in postmenarcheal girls. Users of oral contraceptives showed low or lownormal urinary gonadotropin levels. Surprisingly, gonadotropins were not completely suppressed by oral contraceptives, as most values were within reference ranges. This could in part reflect some samples being collected in the pill-free period.
Attempts have been made to find a more acceptable and available alternative to the invasive GnRH stimulation test, which currently remains the gold standard for diagnosing CPP (27, 28) . One study previously found that urinary LH was equally as good as the GnRH stimulation test in differentiating the clinical appearance of early puberty from prepuberty (8) . In keeping with this, Zung et al. (29) found that urinary LH can differentiate slowly progressive precocious puberty from rapidprogressive precocious puberty in girls. We also found that urinary LH, but not urinary FSH, was elevated among the patients with CPP, and that a urinary LH concentration .2 SD scores was able to predict a positive test result in 75% of the cases. The strong correlation found between urinary LH and GnRH-stimulated serum LH in our study supports clinical use of urinary LH. The correlation is in agreement with previous studies that reported correlation ratios .0.66 between urinary LH and GnRH-stimulated LH (8, 30) .
However, a biochemical evaluation can never stand alone when diagnosing the patients with CPP, and it should be accompanied by bone age evaluation, growth rate, and a thorough clinical examination, including pubertal staging according to Tanner classification. One girl in our study had a peak serum LH of 4.46 IU/L, and was therefore classified with PT; however, she was clinically diagnosed with rapidly progressing central puberty and started on GnRHa therapy. Her urinary LH excretion was ;4 SDs above the reference ranges, making in this case the urinary LH SD score a better diagnostic marker than the GnRH stimulation test.
The adequacy of treatment with GnRH analogs is often monitored by repeating the GnRH stimulation test 90 days after initiation of treatment. In our patient group, all showed a significant decline in peak LH after 3 months, indicating a suppressed HPG axis. This is in accordance with findings from an earlier study evaluating methods of monitoring treatment, where the stimulated peak serum LH in 17 cases all indicated adequate suppression of the HPG axis after performing the GnRH stimulation test (31) . In our study, 5 out of 13 girls with precocious puberty showed an increase in basal serum LH concentration 3 months after start of GnRHa treatment, whereas the last seven patients showed a minor decline in basal serum LH concentration, making basal serum LH levels useless for monitoring treatment efficacy. In contrast, the eight patients for whom FMV urine samples were available at baseline and after 3 months of GnRHa treatment all showed a clear decline in their FMV urinary LH levels, corresponding to the decline seen in the GnRH stimulation test. In fact, all eight patients had an FMV urinary level #+2 SD scores, underlining the potential of FMV urinary LH as a noninvasive tool to monitor GnRH suppression. A previous study found a similar decline in urinary LH in 12 out of 17 girls, and thus inconsistent results in five girls (31) . These authors suggested the possibility that measurement of urinary LH might be able to detect some escapes of the HPG axis suppression, a phenomenon that was not recognized by the GnRH stimulation test. However, future prospective studies are needed to justify implementation of urinary LH measurement in routine monitoring of GnRHa treatment.
Ages at pubertal onset in Copenhagen have been decreasing from 1991 to 2005/2006 (13, 14) . Thus, average age at B2 in girls was 9.9 years compared with 10.9 years 16 years earlier. Similar trends toward earlier pubertal timing have been observed in other Western countries, for example, the United States (32), The Netherlands (33), and in the British ALSPAC cohort (34) . We think that our present data represent an average European white population and that the results can be applied to other European populations.
Studies have tried to adjust the urine for various factors, including creatinine, nonetheless without improving the discriminatory values (21, 22) . We adjusted for osmolality, but found that it did not alter the results. Twenty-four-hour collections of urine have also been studied, showing excellent correlations between 24-hour urine collection and FMV urine, which may suggest that 24-hour urine is superfluous (35) . However, to our knowledge no studies have so far accounted for differences in duration of the collection period before the FMV urine collection. In our study, the children had noted the time they emptied their bladder in the evening/night before and the time of the FMV urine sample. We were therefore able to adjust for the variations of hours since previous void as well as the volume, creating a more standardized measure. However, the discriminatory value of this calculated measure was not superior to the unadjusted urinary LH concentrations. We thus find that the urinary concentration of LH in FMV urine does not need correction for creatinine, osmolality, nor collection period.
In conclusion, our data suggest that FMV urinary concentrations of LH can be used as a diagnostic marker in girls suspected of CPP. Additionally, we suggest measurement of unadjusted FMV urinary concentrations of LH as a method for monitoring treatment with GnRHa in girls with CPP.
